BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 3921242)

  • 1. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
    Wing LY; Garrett WM; Brodie AM
    Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
    Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH
    Cancer Res; 1982 Aug; 42(8 Suppl):3360s-3364s. PubMed ID: 6805949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
    Yamamoto T; Urabe M; Tamura T; Kitawaki J; Honjo H; Okada H
    Anticancer Res; 1991; 11(6):1999-2002. PubMed ID: 1776832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential responses of sex steroid target tissues of rats treated with 4-hydroxyandrostenedione.
    Wing LY; Hammond JO; Brodie AM
    Endocrinology; 1988 Jun; 122(6):2418-27. PubMed ID: 3131115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
    Brueggemeier RW; Li PK
    Cancer Res; 1988 Dec; 48(23):6808-10. PubMed ID: 3141048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
    Iino Y; Karakida T; Sugamata N; Andoh T; Takei H; Takahashi M; Yaguchi S; Matsuno T; Takehara M; Sakato M; Kawashima S; Morishita Y
    Anticancer Res; 1998; 18(1A):171-6. PubMed ID: 9568073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
    Yue W; Wang J; Savinov A; Brodie A
    Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo studies with aromatase inhibitor 4-hydroxy-androstenedione.
    Brodie AM; Wing LY
    Steroids; 1987; 50(1-3):89-103. PubMed ID: 3504069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat.
    Zhou JL; Brodie A
    J Steroid Biochem Mol Biol; 1995 Jan; 52(1):71-6. PubMed ID: 7857875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment with aromatase inhibitor 4-hydroxandrostenedione on the nonhuman primate menstrual cycle.
    Brodie AM; Hammond JO; Ghosh M; Meyer K; Albrecht ED
    Cancer Res; 1989 Sep; 49(17):4780-4. PubMed ID: 2758411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
    De Coster R; Van Ginckel RF; Callens MJ; Goeminne NK; Janssens BL
    Cancer Res; 1992 Mar; 52(5):1240-4. PubMed ID: 1737385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.
    Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH; Williams JG
    J Steroid Biochem; 1983 Jul; 19(1A):53-8. PubMed ID: 6887872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
    Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
    Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors prevent granulosa cell differentiation: an obligatory role for estrogens in luteinizing hormone receptor expression.
    Knecht M; Brodie AM; Catt KJ
    Endocrinology; 1985 Sep; 117(3):1156-61. PubMed ID: 2990868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors.
    Abul-Hajj YJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3373s-3377s. PubMed ID: 6211227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 4-hydroxyandrostenedione and hyperstimulation with pregnant mare serum gonadotrophin on early embryonic development in rats.
    Tong TY; Goh VH
    Can J Physiol Pharmacol; 2001 Sep; 79(9):744-53. PubMed ID: 11599774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
    Tanaka M; Yano S; Hasegawa Y; Nakao K
    Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
    Sugamata N; Koibuchi Y; Iino Y; Morishita Y
    Int J Oncol; 1999 Feb; 14(2):259-63. PubMed ID: 9917500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic studies on aminoglutethimide.
    Salhanick HA
    Cancer Res; 1982 Aug; 42(8 Suppl):3315s-3321s. PubMed ID: 7083193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
    Yue W; Brodie AM
    J Steroid Biochem Mol Biol; 1997; 63(4-6):317-28. PubMed ID: 9459198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.